CRLX101: Phase Ib started

Cerulean began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate IV CRLX101 on days 1 and 15 of a 28-day cycle plus weekly IV paclitaxel in up to 18 patients. Cerulean has exclusive, wor...